Allogeneic Growth Factor Solution to Accelerate Bone Repair BELGRADE, Mont. , May 28, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and wound care disorders, today announced the commercial launch of OsteoFactor Pro™, a naturally occurring cocktail of allogeneic growth factors engineered to improve bone healing and support surgical success across orthopedic and spine procedures.
Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Brett Maas - Hayden IR Sean Browne - President and Chief Executive Officer Scott Neils - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Ryan Zimmerman - BTIG Operator Good afternoon, everyone, and welcome to the Xtant Medical's First Quarter 2025 Financial Results. At this time, all participants are in a listen-only mode, and the floor will be open for questions following the presentation.
Revenue Increases 18% Year-over-Year Delivers Positive Net Income and $1.3 Million in Operating Cash Flow Increases 2025 Revenue Guidance to $127 Million to $131 Million BELGRADE, Mont. , May 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today reported financial and operating results for the first quarter ended March 31, 2025.
Medical - Devices Industry | Healthcare Sector | Sean E. Browne CEO | XSTU Exchange | US98420P3082 ISIN |
US Country | 217 Employees | - Last Dividend | 14 Feb 2018 Last Split | 19 Oct 2015 IPO Date |